Moreover, stroke patients treated with standard management and oral FIN medication beyond the 4.5 h treatment window for intravenous thrombolysis (tissue plasminogen activator) displayed reduced secondary tissue injury, decreased neurological impairments, and improved post-stroke recovery compared to patients who received standard management alone [24]. The gene discussed is PLAT; the disease is stroke disorder.